Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, is now offering the drugs at lower prices for self-pay patients.

On Monday, the company announced it would offer both medications, Ozempic (the weight-loss version of the drug) and Wegovy (the version that addresses diabetes), at a discounted rate of $199 per month for a limited time. The introductory offer goes from now until March 31, 2026. The announcement noted that the pricing is only good for the first two months of treatment, and at the lowest doses of the medications. After the initial months of treatment, the cost will move to the new monthly self-pay rate of $349 per month, down from $499.

“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable an

See Full Page